Cortice Biosciences, Inc.

CNS Pharmaceuticals Secures Orphan Drug Designation for TPI 287 in Brain Cancer Treatment

10 days ago

• CNS Pharmaceuticals has successfully acquired Orphan Drug Designation from Cortice Biosciences for TPI 287, a novel abeotaxane with potential to cross the blood-brain barrier for treating brain tumors. • In early clinical trials, TPI 287 combined with bevacizumab showed promising efficacy against glioblastoma multiforme (GBM), with 3 complete responses and 9 partial responses among 23 evaluable patients. • The company plans to begin patient enrollment for a Phase 2 study by the end of 2025, with the Orphan Drug status potentially providing seven years of market exclusivity upon approval.

BioNTech Advances Oncology Pipeline with BNT327/PM8002 and mRNA Immunotherapies

4 months ago

• BioNTech is progressing BNT327/PM8002, a bispecific antibody, into global clinical trials for first-line small cell lung cancer and non-small cell lung cancer. • The company plans to initiate additional trials combining BNT327/PM8002 with antibody-drug conjugates (ADCs) in 2025, expanding its combination strategy. • BioNTech's mRNA cancer immunotherapy, autogene cevumeran, is being evaluated in a Phase 2 trial for muscle-invasive urothelial carcinoma in combination with nivolumab. • Clinical data readouts are expected in 2025 and 2026 from multiple randomized trials of personalized and off-the-shelf mRNA cancer immunotherapy candidates.